Health

United Imaging Introduces Next-Generation PET/CT Systems and Integrated Molecular Technology Platform at SNMMI

With uMI Panorama™, United Imaging Continues to Push the Envelope on Whole-Body System Performance HOUSTON, June 25, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment and a Leadership Circle sponsor at this year's SNMMI, is ...

2023-06-26 00:00 2504

Momcozy Brings the Latest Breast Pump and Massager Innovations to FIME 2023 in Miami, Empowering Moms Everywhere

MIAMI, June 22, 2023 /PRNewswire/ -- Momcozy , the renowned maternity and baby brand endorsed by over two million moms globally, has showcased its latest wearable breast pumps and massagers at the Florida International Medical Expo (FIME) fromJune 21 to June 23. FIME is the...

2023-06-23 10:00 2231

SK pharmteco doubles viral vector production capacity in Europe

* Yposkesi, SK pharmteco's clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing footprint to10,000m2, one of the largest inEurope * Operation of the second facility to kick sta...

2023-06-23 07:30 2255

Bergen Conference Marks 150 Years Since Discovery of the Leprosy Bacillus

TOKYO, June 22, 2023 /PRNewswire/ -- A two-day conference commemorating the discovery of the bacillus that causes leprosy 150 years ago took place in Bergen, Norway, on June 21-22, 2023. Organized by the Sasakawa Leprosy (Hansen's Disease) Initiative and the University of Bergen, the conference i...

2023-06-22 22:00 2367

Holmusk and Streamline Healthcare Solutions Announce Strategic Partnership To Bring Behavioral Health Predictive Analytics Tool to US Market

Initial phase will bring MaST, Holmusk's tool to help healthcare professionals better prioritize and manage behavioral health caseloads, to Mental Health Partners inColorado NEW YORK, June 22, 2023 /PRNewswire/ -- Holmusk , a leading global behavioral health real-world ...

2023-06-22 21:35 2075

I-Mab Announces the Appointment of Raj Kannan as CEO

GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan...

2023-06-22 20:00 2481

PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES

The Sponsored Research Agreement will help advance antidepressant treatments for patients in need SYDNEY, June 22, 2023 /PRNewswire/ -- Biotech start-up, Psylo, announced today that it has entered into a Sponsored Research Agreement with global Japanese pharmaceutical company, Daiichi Sankyo (DS...

2023-06-22 19:00 2052

Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry

TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...

2023-06-22 13:00 2065

BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease

WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the initiation of a randomized, placebo-controll...

2023-06-22 08:02 2220

Dr. Yinfei Yin Joins Shanghai ChemPartner as Vice President and Head of Biology and Pharmacology

SHANGHAI, June 21, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Yinfei Yin, Ph.D. as vice president of and head of the biology and pharmacology department at Shanghai ChemPartner. Dr. Yin brings a wealth of experience and expertise to his new ...

2023-06-21 23:07 2179

Mediso receives FDA approval for InterView™ nuclear medicine image processing software

BUDAPEST, Hungary, June 21, 2023 /PRNewswire/ -- Mediso has announced the Food and Drug Administration (FDA) clearance of theInterView™ FUSION andInterView™ XP

2023-06-21 16:00 2067

Nuvilab Awarded as 2023 Technology Pioneer by World Economic Forum

* The World Economic Forum announces selection of the 100 most promising Technology Pioneers, companies that are tackling such issues as sustainability, climate change and healthcare. * Nuvilab, the South Korean food-tech startup with the core technology that analyses food and nutrition intak...

2023-06-21 15:30 2175

bioSeedin attended 2023 BIO international convention for international licensing and partnership

BOSTON, June 19, 2023 /PRNewswire/ -- bioSeedin, a global transaction and consultation platform, attended as an exhibitor at the world's largest biotech trade event BIO international convention, held inBoston from June 5th to June 8th, 2023. During the four-day event, to better connect promising...

2023-06-21 11:44 1882

Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan

TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered inTokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of...

2023-06-21 09:00 2819

Growing Awareness of Brain Health for Senior Dogs as Cascade Animal Sciences Launches "Neuro-Pro"

ATLANTA, June 20, 2023 /PRNewswire/ -- Cascade Animal Sciences, an animal health start-up based inthe United States and Australia, is proud to announce the launch of its first dietary supplement product "Neuro-Pro".  Neuro-Pro is designed for middle-to-senior-aged dogs and dogs that require neuro...

2023-06-20 22:17 2231

Clarity commences COMBAT theranostic prostate cancer trial in the US

SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its64C...

2023-06-20 21:03 2004

Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023

SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other autoimmune diseases, announced the preliminary phase I data of LP-003 ...

2023-06-20 21:00 1888

Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors

SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies a...

2023-06-20 18:30 4968

Together for Health - Parenting the Future: Symposium on Fertility Support and Childcare Development in Rural Areas Held in Xi'an, China

* Hupan Modou Foundation and Shaanxi Provincial Government foster innovation through multi-party cooperation to enhance rural childcare services * Parenting the future: After 5 years of development and wide-reaching impact, Hupan Modou launches project in Zhenba,Shaanxi XI'AN, China, June 20, ...

2023-06-20 11:53 1082

Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023

* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma * Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEO...

2023-06-20 08:01 1103
1 ... 88899091929394 ... 280